MonitoringReportsMethodologyPricingBlogAboutStart for free
τTaufolioEarnings · US
Earnings / US / Eli Lilly and Company
Q3 2026 · call Oct 29, 2026

Eli Lilly and Company earnings Q3 2026

Share reaction
▲ +6.6%Oct 28 → Oct 29 · #6 of 23 this season
The gist

Eli Lilly shares rose 6.6% following an earnings release that beat analyst expectations across both top and bottom lines, driven by continued surging demand for its flagship incretin therapies. Third-quarter revenue jumped 38.6% year-over-year to $24.4 billion, outpacing the analyst consensus of $22.62 billion, while non-GAAP earnings per share reached $7.48 against an expected $6.61. Sales of diabetes and obesity treatments Mounjaro and Zepbound powered the outperformance, prompting management to raise full-year revenue guidance to between $91 billion and $92 billion. Executive commentary framed the moment as "the middle of the largest new category expansion in the history of the pharmaceutical industry," reassuring investors that underlying patient uptake remains durable enough to absorb ongoing price reductions across key markets.

Revenue$24.4B+39% y/y
Operating income$8.61B+17% y/y
Net income$6.45B+16% y/y
Share price chart, Eli Lilly and Company
Full report: 9 sectionsthe first sentence of each section is public, the rest with a free account
🔒Takeaways from the whole briefEli Lilly delivered another very strong quarter, led by Mounjaro and Zepbound and by broad volume growth that overwhelmed falling realized prices.
🔒Management commentaryEli Lilly delivered strong third-quarter revenue growth of 39% year over year to $24.40 billion, driven primarily by high-volume demand for incretin treatments Mounjaro and Zepbound.
🔒Guidance qualityLilly raised 2026 revenue guidance to $91–92 billion from $85–87 billion.
🔒Capital allocationLilly is prioritizing manufacturing and future medicines while maintaining shareholder returns.
🔒Accounting qualityRevenue of $24.40 billion and earnings per share of $7.22, both under generally accepted accounting principles (GAAP), match the quarterly filing.
🔒Quarter-to-quarter continuityQ3 2026 strengthens the evidence that broader access can generate enough treatment growth to outweigh falling prices, even though revenue growth slowed from Q2.
🔒Earnings scorecardResults against expectations, line by line
🔒Analyst Q&AWhat analysts asked and how concretely management answered
🔒Management toneAnalysts at Citigroup highlighted that third-quarter revenue came in well ahead of consensus estimates, with flagship treatments Mounjaro and Zepbound generating the vast majority of outperformance (marketscreener.com).
Create a free account →no card · 100 credits a month

Questions and answers

What did Eli Lilly and Company report for Q3 2026?

Revenue: $24.4B; Operating income: $8.61B; Net income: $6.45B.

How did Eli Lilly and Company shares react?

Up 6.6%: from the close on Oct 28, 2026 (before call day) to the close on Oct 29, 2026. That is #6 of 23 companies this season.

What is in the full report?

Takeaways from the whole brief, Management commentary, Guidance quality, Capital allocation, Accounting quality, Quarter-to-quarter continuity, Earnings scorecard, Analyst Q&A, Management tone.

How to read it

Cookies and analytics

Essential cookies keep you signed in. Analytics runs only if you agree.